Please check your internet connection and try again.
# TUSQD
## Overview
TUSQD is a combination medication containing **guaifenesin** and **dextromethorphan**. Guaifenesin is an expectorant that thins and loosens mucus. Dextromethorphan is a cough suppressant that acts on the cough center in the brain.
## Primary Indications
* Relief of cough due to minor throat and bronchial irritation.
* Helps loosen phlegm (mucus) and thin bronchial secretions to make coughs more productive.
## Adult Dosing
* **Guaifenesin 600 mg / Dextromethorphan HBr 30 mg extended-release tablets:**
* Take 1 tablet every 12 hours.
* Do not exceed 2 tablets in 24 hours.
## Pediatric Dosing
Dosing for pediatric patients is not well-established for this specific extended-release formulation. **Consult specific pediatric guidelines or product monographs for age-appropriate dosing of individual components (guaifenesin and dextromethorphan) if using a different formulation.** Generally, dextromethorphan should be used with caution in children under 6 years old.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment recommendations are provided in the labeling. Monitor for adverse effects.
* **Renal Impairment:** Use with caution. No specific dose adjustment recommendations are provided in the labeling. Monitor for adverse effects.
## Contraindications
* Hypersensitivity to guaifenesin or dextromethorphan.
* Use within 14 days of starting or stopping a monoamine oxidase inhibitor (MAOI).
## Adverse Effects
* **Common:** Nausea, vomiting, dizziness, drowsiness, headache.
* **Less Common:** Rash, gastrointestinal upset, constipation, confusion.
* **Serious:** Serotonin syndrome (especially with concomitant serotonergic agents), respiratory depression (in overdose or in patients with underlying respiratory conditions), allergic reactions.
## Key Drug Interactions
* **Monoamine Oxidase Inhibitors (MAOIs):** Concomitant use is contraindicated due to risk of serotonin syndrome or hypertensive crisis.
* **Serotonergic Agents (e.g., SSRIs, SNRIs, triptans):** Increased risk of serotonin syndrome.
* **Central Nervous System (CNS) Depressants (e.g., alcohol, sedatives, hypnotics):** May increase CNS depressant effects.
* **CYP2D6 Inhibitors (e.g., fluoxetine, paroxetine, quinidine):** May increase dextromethorphan levels, increasing the risk of toxicity.
## Monitoring
* Monitor for signs and symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle rigidity, nausea, vomiting, diarrhea).
* Assess cough frequency and sputum production.
* Monitor for adverse effects such as dizziness, drowsiness, and gastrointestinal upset.
## Clinical Pearls
* This extended-release formulation should be swallowed whole and not crushed, chewed, or broken.
* Adequate fluid intake can help loosen mucus and should be encouraged.
* Effectiveness in patients with chronic cough (e.g., asthma, emphysema) is not established.
* Dextromethorphan can be misused or abused.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the current prescribing information and relevant literature for complete and up-to-date details before making any clinical decisions.
